Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,440 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07073534RecruitingPhase 1/Phase 2
A study of two drugs for advanced solid tumors
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT07069062RecruitingPhase 1/Phase 2
Study of HY0001a for Advanced Solid Tumors
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07070999RecruitingPhase 1/Phase 2
Gene therapy GB221 for infants with SMA type 1
This trial tests a new gene therapy called GB221 for infants with SMA type 1, a rare muscle-weakening disease. It aims to see if this treatment can improve muscle strength and development, and it is for babies who have not had prior gene therapy.
Porto Alegre, Rio Grande do SulAges 2 weeks–1 year - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07067567RecruitingPhase 1
Study of AK146D1 injection for advanced solid tumors
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07071090RecruitingPhase 1
Study of DC50292A for advanced solid tumors with MTAP deletion
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Fuzhou, FujianAges 18 years+ - NCT07068932RecruitingPhase 1
Study of SHR-4506 for advanced solid tumors
This trial tests a new drug, SHR-4506, for people with advanced cancers that have stopped responding to standard treatments or cannot be treated with standard options. It aims to see if the drug is safe and helpful.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07069556Recruiting
ColoSense stool test study before colonoscopy
This study is testing a new stool-based screening test for colorectal cancer. You provide a stool sample before having a colonoscopy, and researchers compare the test results with what the colonoscopy finds.
St Louis, MissouriAges 18 years+ - NCT07069335RecruitingPhase 1
Studying a new form of olaparib for BRCA-mutated ovarian cancer
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Seoul, Songpa DistrictAges 19–74 - NCT07075328RecruitingPhase 1/Phase 2
Study of OJP-001 for adult T-cell leukemia/lymphoma
This trial tests a new drug called OJP-001 for people with adult T-cell leukemia/lymphoma (ATL) that has come back or not responded to other treatments. The goal is to see if this drug can help control the disease.
Fukuoka, FukuokaAges 20–85 - NCT07073014Enrolling by invitationPhase 3
Long-term continuation of a follow-up study for a children's genetic condition called something in the world of a person who is like a head or foot specialist? Probably? (shortest version? of? a? person? condition? that? is? so? far? less? than? 60?? (time? of? a? person? limited???)?
this study is a long-term extension of the main study for the drug which from Bio? bi? whatever? in the name? by?...????
Phoenix, ArizonaAges Any age - NCT07073677RecruitingPhase 2
Testing a new eczema ointment for mild to moderate cases
This study tests a new ointment called IN-115314 for adults with mild to moderate eczema. Researchers want to see if it helps control symptoms like itching and redness better than a placebo, and check that it's safe to use.
Ansan, ALLAges 19 years+ - NCT07066826RecruitingPhase 2/Phase 3
Huperzine A for mild-to-moderate Alzheimer's dementia
This study tests whether Huperzine A controlled-release tablets can help improve memory and thinking in people with mild-to-moderate Alzheimer's disease. You'll take the tablets or a placebo to see if it slows down dementia symptoms.
BeijingAges 50–85 - NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
Palo Alto, CaliforniaAges 1 year+ - NCT07066657RecruitingPhase 1
Study of MRG007 for advanced solid tumors
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Los Angeles, CaliforniaAges 18 years+ - NCT07070232RecruitingPhase 1/Phase 2
Testing a new drug BNT326 for advanced cancers
This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT07069569RecruitingPhase 2
AHB-137 injection combined with other hepatitis B drugs
This study tests a new injection called AHB-137 combined with other hepatitis B drugs. It aims to see if the combination can better control the virus in people with chronic hepatitis B who are already on antiviral pills.
Beijing, Beijing MunicipalityAges 18–65 - NCT06983652Recruiting
Validating a new scan for corneal scars and swelling
This study tests a new scanning technology (terahertz) to see if it can detect and measure corneal scars and swelling (edema). If you have one of these conditions, you may help validate a faster, non-invasive way to monitor your eye health.
SingaporeAges 21 years+ - NCT06982989Recruiting
Wearable light therapy for pelvic pain
This study tests a wearable device that uses LED light to treat pelvic pain. It may be an option for people who want a non-medicine approach to managing their pain.
Beijing, Beijing MunicipalityAges 18–35 - NCT06983613Recruiting
New heart rhythm after PFO closure study
This study looks at whether closing a small hole in the heart (called a PFO) can cause new heart rhythm problems. It is for people who had a stroke caused by a PFO and are planning to have it closed.
PragueAges 18 years+ - NCT06382519Recruiting
Thalidomide for Very Early-Onset IBD in Kids
This study tests whether the drug thalidomide can help children with very early-onset inflammatory bowel disease (VEOIBD) when their symptoms are moderate to severe. It aims to see if thalidomide can calm the inflammation and improve quality of life.
Shanghai, Shanghai MunicipalityAges 4 weeks–6 years - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65 - NCT07067229Recruiting
Brain stimulation and exercise for motor neuron disease
This study tests whether combining non-invasive brain stimulation (a gentle, non-surgical treatment) with exercise can help people with motor neuron disease (MND). It may improve movement and quality of life for those with mild to moderate symptoms.
Bangkok, PathumwanAges 18–80
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,440 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.